Irish speciaty pharma firm Shire will shell out $100 million upfront to acquire FerroKin BioSciences Inc, a Bay area company that is developing a drug that can potentially eliminate excess iron in the blood. The Dublin-based Shire said in a statement that it will pay $100 million upfront to ...

NicOx and its partner Bausch & Lomb reported positive top-line results from a mid-stage study of their glaucoma drug candidate BOL‑303259‑X. The companies are moving the potential treatment to reduce  fluid pressure inside the eye into phase III development.   The French biotech firm NicOx had ...

GlaxoSmithKline has started a collaboration with UK biotech and personalized medicine company Epistem  on fibrosis related research. The financial details were not disclosed. The Manchester, UK-based Epistem said the three-year biomarker research collaboration with GSK will focus on identifying key characteristics of ...

Pfizer Inc has ended the $350 million deal to commercialize Biocon's biosimilar versions of insulin and insulin analogues, giving a big blow to the India biopharma firm's ambitions to emerge as a major player in diabetes care. The two company said that all rights ...

Johnson & Johnson's Janssen unit said that its prostate cancer drug Zytiga (abiraterone acetate) delayed the progression of cancer in chemotherapy-naive patients. The late-stage trial COU-AA-302 of Zytiga in 1,088 patients with castration-resistant prostate cancer has been unblinded due its effectiveness, ...

Apogenix' experimental protein drug APG101 has achieved its primary target in a mid-stage clinical trial evaluating the agents efficacy as the second line treatment of Glioblastoma Multiforme (GBM), the most common and most aggressive form of brain cancer. The German biotech firm, ...

Millennium will initiate an international Phase III clinical study to evaluate its experimental cancer drug  in patients with relapsed or refractory peripheral T-cell lymphoma, an aggressive form of non-Hodgkin's lymphoma. Millennium,  Takeda's oncology unit, said the multi-centre late-stage trial for the ...

Forest Laboratories reported positive late-stage clinical trial data of levomilnacipran, an investigational drug for the treatment of adults with major depressive disorder (MDD). The New York-based drugmaker Forest Labs said in a statement that patients with MDD treated with levomilnacipran showed ...

Discovery Laboratories was boosted by the news that the U.S. FDA finally approved its Surfaxin (lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants with high risk of the breathing disorder. The US specialty pharma firm has previously ...

Lundbeck reported promising data of three late-stage trial showing that its alcohol dependence drug nalmefene (Selincro) reduces alcohol consumption by an average of 66 percent in people with alcohol dependence. The Danish pharma firm Lundbeck and its partner Biotie Therapeutics showed the ...